Prednylidene is an experimental systemic glucocorticoid.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Prednylidene. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednylidene. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Prednylidene. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Prednylidene. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Prednylidene. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Prednylidene. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Prednylidene. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednylidene. |
| Pegaspargase | The serum concentration of Prednylidene can be increased when it is combined with Pegaspargase. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednylidene. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednylidene. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Prednylidene. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednylidene. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Prednylidene. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednylidene. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednylidene. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednylidene. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Prednylidene. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednylidene. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednylidene. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednylidene. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednylidene. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednylidene. |
| Cladribine | Prednylidene may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Prednylidene. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Prednylidene. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Prednylidene. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Prednylidene. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Prednylidene. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Prednylidene. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Prednylidene. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Prednylidene. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Prednylidene. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednylidene. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Prednylidene. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Prednylidene. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Prednylidene. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Prednylidene. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Prednylidene. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Prednylidene. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Prednylidene. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Prednylidene. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednylidene. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Prednylidene. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednylidene. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Prednylidene. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Prednylidene. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Prednylidene. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Prednylidene. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednylidene. |
| Tretinoin | The metabolism of Tretinoin can be increased when combined with Prednylidene. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Prednylidene. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Prednylidene. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Prednylidene. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Prednylidene. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Prednylidene. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Prednylidene. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Prednylidene. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Prednylidene. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednylidene. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Prednylidene. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Prednylidene. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Prednylidene. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Prednylidene. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Prednylidene. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Prednylidene. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Prednylidene. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Prednylidene. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Prednylidene. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Prednylidene. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Prednylidene. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Prednylidene. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Prednylidene. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Prednylidene. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Prednylidene. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Prednylidene. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Prednylidene. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Prednylidene. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Prednylidene. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Prednylidene. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Prednylidene. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Prednylidene. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Prednylidene. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Interferon alfa is combined with Prednylidene. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Prednylidene. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Prednylidene. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Prednylidene. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Prednylidene. |
| Abetimus | The risk or severity of adverse effects can be increased when Abetimus is combined with Prednylidene. |
| Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Prednylidene. |
| Bendamustine | The risk or severity of adverse effects can be increased when Bendamustine is combined with Prednylidene. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Prednylidene. |
| Wortmannin | The risk or severity of adverse effects can be increased when Wortmannin is combined with Prednylidene. |
| Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Prednylidene. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Prednylidene. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednylidene. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Carfilzomib is combined with Prednylidene. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Prednylidene. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Prednylidene. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Vedolizumab is combined with Prednylidene. |